ENDRA Life Sciences Reports Increased Net Loss and Rising Operating Expenses in Q1 2026

ENDRA Life Sciences Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.31 million, an increase from a net loss of $1.04 million in the same period last year. The company's total operating expenses rose to $2.17 million, compared to $1.47 million in the prior year, driven primarily by a 47% increase in research and development expenses, which reached $776,410. This increase reflects the company's ongoing commitment to the development of its Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology, aimed at improving liver fat measurement for metabolic disease management.

In terms of financial position, ENDRA's total assets decreased to $3.44 million as of March 31, 2026, down from $3.85 million at the end of 2025. The decline was attributed to a reduction in cash reserves, which fell to $356,462 from $762,365, and a decrease in fixed assets. Current liabilities also increased to $835,440, up from $750,956, primarily due to higher accounts payable and accrued liabilities. The company's stockholders' equity decreased to $1.79 million, down from $2.26 million, reflecting the cumulative losses incurred since inception.

Strategically, ENDRA has expanded its business model to include a Digital Asset Treasury (DAT) initiative, which aims to optimize capital preservation and generate returns through investments in decentralized finance assets. This initiative is intended to complement the commercialization of the TAEUS platform, which is being developed for a subscription-based revenue model targeting the growing markets for GLP-1 and metabolic disease treatments. The company has also initiated a review of strategic alternatives, including potential mergers or collaborations, to enhance its financial position and operational capabilities.

Operationally, ENDRA has not yet generated revenue from its TAEUS technology, which remains in development. The company has implemented cost-reduction measures, including a reduction in headcount, to extend its operational runway. As of March 31, 2026, ENDRA had a total of 1,240,751 shares of common stock outstanding, reflecting a modest increase from the previous quarter. The company continues to face challenges in securing adequate financing to support its ongoing operations and product development efforts.

Looking ahead, ENDRA's management has indicated that additional capital will be necessary to fund operations and advance the commercialization of its TAEUS technology. The company is exploring various financing options, including potential equity offerings, but acknowledges the uncertainty surrounding its ability to secure sufficient funding. The financial statements have been prepared under the assumption that the company will continue as a going concern, although there is substantial doubt regarding its ability to do so without additional financing.